Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sonnet Biotherapeutics Holdings Inc SONN

Consumer Cyclical Biotechnology
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. Its technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. It designed the... see more

Recent & Breaking News (NDAQ:SONN)

Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum

Accesswire June 2, 2022

Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update

Accesswire May 10, 2022

Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors

Accesswire April 13, 2022

Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Accesswire April 8, 2022

Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors

Accesswire March 16, 2022

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting

Accesswire February 9, 2022

Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update

Accesswire February 8, 2022

Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update

Accesswire December 17, 2021

Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)

Accesswire August 30, 2021

Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering

Accesswire August 19, 2021

Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update

Accesswire August 16, 2021

Sonnet BioTherapeutics Announces Change in Date of Annual Meeting

Accesswire June 14, 2021

Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology

Accesswire June 8, 2021

Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update

Accesswire May 17, 2021

Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)

Accesswire May 10, 2021

Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics

Accesswire May 3, 2021

Sonnet BioTherapeutics Provides 2021 Business Update

Accesswire March 29, 2021

Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations

Accesswire March 22, 2021

Sonnet BioTherapeutics Provides Fiscal Year 2021 First Quarter Business and Earnings Update

Accesswire February 16, 2021

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021 Annual Meeting

Accesswire February 3, 2021